Key terms
About XENE
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XENE news
Today
9:08am ET
Xenon Pharmaceuticals Spotlights XEN1101 Progress
Apr 12
6:35am ET
Buy Rating Affirmed for Xenon: A Comprehensive Analysis of Market Position and Growth Prospects
Apr 04
4:37pm ET
Xenon Pharmaceuticals at Needham Healthcare Conference
Mar 12
4:38pm ET
Xenon Pharmaceuticals Engages at Stifel CNS Event
Mar 05
4:48pm ET
Xenon Pharmaceuticals Spotlight at Biopharma Conference
Mar 05
1:35am ET
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
Mar 04
9:16am ET
Xenon Pharmaceuticals price target raised to $62 from $49 at Guggenheim
Mar 01
9:17am ET
Xenon Pharmaceuticals price target raised to $62 from $50 at Needham
Mar 01
8:24am ET
Xenon Pharmaceuticals price target raised to $51 from $46 at Wedbush
Mar 01
8:20am ET
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)
Mar 01
7:51am ET
Xenon Pharmaceuticals price target raised to $55 from $48 at Wells Fargo
Mar 01
7:49am ET
Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)
Mar 01
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Xenon (XENE)
Mar 01
7:06am ET
Analysts’ Top Healthcare Picks: Xenon (XENE), Ascendis Pharma (ASND)
Mar 01
7:05am ET
Xenon’s Advancing Drug Portfolio and Financial Stability Affirm Buy Rating with Raised Price Target
Mar 01
7:02am ET
Buy Rating Affirmed for Xenon’s Stock Amidst Clinical Advancements and Robust Pipeline
Mar 01
6:26am ET
Buy Rating Affirmed for Xenon on Promising Drug Development and Strong Financial Strategy
Mar 01
5:21am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)
Mar 01
2:45am ET
Buy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neuroscience
Feb 29
10:05pm ET
TD Cowen Sticks to Their Buy Rating for Xenon (XENE)
Feb 29
4:23pm ET
Xenon Pharmaceuticals Engages Investors Across Multiple Platforms
Feb 29
4:04pm ET
Xenon Pharmaceuticals reports Q4 EPS (64c), consensus (76c)
Feb 23
11:55am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 23
11:00am ET
JPMorgan biotech analysts to hold an analyst/industry conference call
Feb 09
8:31am ET
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Disc Medicine (IRON) and Renalytix AI (RNLX)
No recent press releases are available for XENE
XENE Financials
Key terms
Ad Feedback
XENE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XENE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
